Thursday, March 23, 2023
As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.
Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.
Professor
Department of Psychiatry and Molecular Medicine
Donald and Barbara Zucker School
of Medicine at Hofstra/Northwell
Hempstead, New York, United States
Professor and Chair
Department of Child and Adolescent Psychiatry
Charité University Medicine
Berlin, Germany
None of the nonfaculty planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.
Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™
ABIM Diplomates - maximum of 0.25 ABIM MOC points
This activity is intended for psychiatrists and primary care providers (PCPs) involved in the care of patients with schizophrenia.
The goal of this activity is to help clinicians increase their awareness of the spectrum of symptoms associated with schizophrenia, the uses and limitations of current antipsychotic medications, and the rationale and clinical data for investigational therapies being studied for the management of schizophrenia.
Upon completion of this activity, participants will:
As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.
Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.
Professor
Department of Psychiatry and Molecular Medicine
Donald and Barbara Zucker School
of Medicine at Hofstra/Northwell
Hempstead, New York, United States
Professor and Chair
Department of Child and Adolescent Psychiatry
Charité University Medicine
Berlin, Germany
None of the nonfaculty planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.
Presented through a collaboration between CMEology and Medscape Education.
Medscape, LLC designates this enduring material for a maximum of 0.25
AMA PRA Category 1 Credit(s)™
. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive
AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME / ABIM MOC Released: 8/2/2021; Reviewed and Renewed: 9/14/2022
Valid for credit through: 9/14/2023
processing....
5-HT1A = serotonin (5-hydroxytryptamine) receptor type 1A
5-HT2A = serotonin (5-hydroxytryptamine) receptor type 2A
ACh = acetylcholine
AE = adverse event
BLA = basolateral amygdala
BNSS = Brief Negative Symptom Scale
CB2 = cannabinoid type 2
CGI-S = Clinical Global Impressions Scale
D1 SPN = D1 receptor-positive spiny projection neurons
D2-receptor = dopamine receptor type 2
DA = dopamine
EPS = extrapyramidal symptoms
GASS = Glasgow Antipsychotic Side-Effect scale
GLP-1 = glucagon-like peptide 1
LTD = long-term depression
M1 = muscarinic receptor type 1
M4 = muscarinic receptor type 4
MADRA = Montgomery-Åsberg Depression Rating Scale
mGlu1 = metabotropic glutamate receptor 1
mITT = modified intention-to-treat
MMRM = mixed model for repeated measures
MOA = mechanism of action
NNT = number needed to treat
NSA-16 = 16-item negative symptom assessment
OC = observed cases
OLA/SAM = olanzapine/samidorphan
OLE = open-label extension
PANSS = Positive and Negative Syndrome Scale
PBO = placebo
PCP = primary care provider
PET = positron emission tomography
PK/PD = pharmacokinetics/pharmacodynamics
PYY = peptide YY
QTc = corrected QT interval
RCT = randomized controlled trial
SCZ = schizophrenia
SE = side effect
SNpc = substantia nigra pars compacta
SNr = substantia nigra reticulata
SNRI = serotonin and norepinephrine reuptake inhibitor
SSRI = selective serotonin reuptake inhibitor
Sx = symptoms
TAAR1 = trace amine associated receptor type 1
TD = tardive dyskinesia
TRS = treatment-resistant schizophrenia
VAS = visual analog scale
vHipp = ventral hippocampus
VTA = ventral tegmental area
XAN + TROP = xanomeline + trospium chloride
| « Return to: Balancing Efficacy and Safety in Schizophrenia: Current and Emerging Approaches |
